Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT

Zachariah DeFilipp, Rafael F. Duarte, John A. Snowden, Navneet S. Majhail, Diana M. Greenfield, Jose Lopez Miranda, Mutlu Arat, K. Scott Baker, Linda J. Burns, Christine N. Duncan, Maria Gilleece, Gregory A. Hale, Mehdi Hamadanin, Betty K. Hamilton, William J. Hogan, Jack W. Hsu, Yoshihiro Inamoto, Rammurti T. Kamble, Maria Teresa Lupo-Stanghellini, Adriana K. MalonePhilip L. McCarthy, Mohamad Mohty, Maxim Norkin, Pamela Paplham, Muthalagu Ramanathan, John M. Richart, Nina Salooja, Hendricus Schouten, Helene Schoemans, Adriana Seber, Amir Steinberg, Baldeep M. Wirk, William A. Wood, Minoo Battiwalla, Mary E. D. Flowers, Bipin N. Savani, Bronwen E. Shaw*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

34 Citations (Web of Science)


Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus, and all-cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with an estimated prevalence of MetS of 31% to 49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal to review literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.
Original languageEnglish
Pages (from-to)1493-1503
JournalBiology of Blood and Marrow Transplantation
Issue number8
Publication statusPublished - Aug 2016


  • Metabolic syndrome
  • Cardiovascular disease
  • Hematopoietic cell transplantation
  • Survivorship
  • Late effects

Cite this